A Study and Report on Impact of Pharmacovigilance and Drug Safety Monitoring Practices in Promotion of Rational Drug Usage in General Medicine Departments of Hospital
Abstract
Keywords
Full Text:
PDFReferences
Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. Ther Clin Risk Manag 2005;1(3):181-8.
Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol 2009;9(14):1-8.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255–9.
National Pharmacovigilance Protocol Ministry of Health & Family Welfare, Government of India. National pharmacovigilance program. Available from: URL:http://www.jipmer.edu/charu/NPVP%20for%20Web.doc.
Rawlins MD. Clinical pharmacology-adverse drug reactions. BMJ 1981 Mar;282:974-6.
Meyboom RHB, Lindquist M, Egberts ACG. An ABC of Drug-Related Problems. Drug Saf 2000 Jun;22(6):415-23.
Pilai AM. Pharmacovigilance and adverse drug reaction reporting; commentary. KMJ 2009; 4:188-90.
Calis KA, Young LR. Clinical analysis of adverse drug reactions. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. 2nd edition. New York (NY): Academic Press; 2016. p. 389-402.
Guidelines for Preparing Core Clinical Safety Information on Drugs - Report of CIOMS Working Group III. Geneva, WHO, 1995. Available from:URL:http://www.who-umc.org/DynPage.aspx?id=22684.
Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003 Nov;68(9):1781-90.
Palaian S, Mishra P, Shankar PR, Dubey AK, Almeida R. Safety monitoring of drugswhere do we stand? Kathmandu Univ Med J 2006;4(13):119-27.
WHO. Policy perspectives on medicines. Pharmacovigilance: ensuring the safe use of medicines. Geneva: World Health Organization 2004 Oct: p 1. Available from: URL:http://www.who.int/medicines/
L. Harmark, A. C. van Grootheest. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 20014;64:743-52.
Munasinghe TMJ. Adverse drug reactions: monitoring, reporting and prevention. Ceylon Med J 2002 Mar;47(1):19-21.
Pirmohamed M, Dodoo A, Winstanley P. Pharmacovigilance in developing countries. BMJ 2007;335:462.
Stephens M. The history of pharmacovigilance. In: Talbot J, Waller P, editors. A text book of Stephen’s detection of new adverse reactions. 5th ed. British library; 2004. p.8-10.
WHO. The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva. World Health Organization 2006: p 21. Available from: URL:http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf.
Gossell-Williams M, Adebayo SA. The PharmWatch programme: challenges to engaging the community pharmacists in Jamaica. Pharmacy Practice (Internet) 2008 Oct-Dec;6(4):187-90.
Kavitha D. Adverse drug reaction (ADR) monitoring and pharmacovigilance. JPRHC 2010 Jan;2(1):127-34.
van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions Pharmacoepidemiol Drug Saf 2002;11:205–10.
Wiedenmayer K, Summers RS, Mackie CA, Gous AGS, Everard M. Pharmacists in the health care team: a policy perspective. In: World Health Organization and International Pharmaceutical Federation 2006. A handbook of developing pharmacy practice-a focus on patient care. 2006th ed; p 12. Available from:URL:http://www.fip.org/files/fip/publications/DevelopingPharmacyPractice/DevelopingPharmacyPracticeEN.pdf.
van Grootheest AC, de Jong-van den Berg LTW. The role of hospital and community pharmacists in pharmacovigilance. Res Social Adm Pharm 2005;1:126-33.
Basak SC, Sathyanarayana D. Community Pharmacy Practice in India: Past, Present and Future. Southern Med Review 2015;2(1):11-14.
Rabbur RSM, Emmerton L. An introduction to adverse drug reaction reporting systems in different countries. Int J Pharm Pract 2017 Mar;13(1):91-100.
Palaian S, Mishra P, Izham M, Celen A. Community pharmacovigilance in Nepal: a guide for community pharmacists. A publication of the Regional Pharmacovigilance Centre 2008, Manipal Teaching Hospital, Pokhara, Nepal. Available from: URL:http://www.haiap.org/wordpress/wp-content/uploads/2008/08/PV-booklet-20thNov.pdf.
Palaian S, Ibrahim MIM, Mishra P. Pattern of adverse drug reactions reported by the Community pharmacists in Nepal. Pharmacy Practice (Internet) 2010 JulSep;8(3):201-7.
Young R, Wurtzbacher D, Blankenship SC. Adverse drug reactions: a review for healthcare practitioners. Am J Manag Care 1997;3(12):1884-1910.
van Grootheest AC, de Jong-van den Berg LTW, Mes K. Attitudes of community pharmacists in Netherlands towards adverse drug reaction reporting. Int J Pharm Pract 2002 Dec; 10:267-72.
Basak SC, Sathyanarayana D. Community pharmacy based research activity in India: a bibliometric study of the past ten years. Southern Med Review 2010 Feb;3(1):7-10.
Chandra Rakesh Raja P, Ramesh A. Design and implementation of adverse drug reaction reporting system in community pharmacies. ijopp 2009 Apr;2(2):31-7.
Basak SC, Sathyanarayana D. Evaluating medicines dispensing patterns at private community pharmacies in Tamilnadu, India. Southern Med Review 2016;3(2):27-31.
Adepu R, Nagavi BG. General practitioners’ perceptions about the extended roles of community pharmacists in the state of Karnataka: a study. Indian J Pharm Sci 2006 Feb;68(1):36-40.
Tobaiqy M, Stewart D, Bond C, Lee A, Helms P, McLay JS. Views of parents and pharmacists following participation in a paediatric pharmacovigilance study. Pharm World Sci 2010; 32:334-8.
Ramesh M, Parthasarathi G. Adverse drug reactions reporting: attitudes and perceptions of medical practitioners. AJPCR 2009;2(2):10-14
Palaian S, Izham M, Mishra P, Arjun P. Knowledge, attitude and practices of the community pharmacists in Nepal towards adverse drug reactions and pharmacovigilance. ijopp 2009 Dec;2(4):2937.
Bawazir SA. Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction reporting. Saudi Pharm J 2006 Jan;14(1):75-83.
Ting KN, Stratton-Powell DM, Anderson C. Community pharmacists’ views on adverse drug reactions reporting in Malaysia: a pilot study. Pharm World Sci 2010 Jun;32(3):339-42.
Tobaiqy M, Stewart D, Bond C, Lee AJ, Bateman N, McCaig D et al. A pilot study to evaluate a community pharmacy–based monitoring system to identify adverse drug reactions associated with paediatric medicines use. Eur J Clin Pharmacol 2014; 66:627–32.
Stewart D, Helms P, McCaig D, Bond C, McLay J. Monitoring adverse drug reactions in children using community pharmacies: a pilot study. Br J Clin Pharmacol 2005 June;59(6):677-83.
Layton D, Sinclair HK, Bond CM, Hannaford CM, Shakir SAW. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf 2002 Sept;11(2):503-13.
Jarernsiripornkul N, Krska J, Capps PAG, Richards RME, Lee A. Patient reporting of potential adverse drug reaction: a methodological study. Br J Clin Pharmacol 2002 Mar; 53:318-25.
Thomas RA. Developing structured-learning exercises for a community advanced pharmacy practice experience. Am J Pharm Educ 2006 Feb;70(1):23.
Oshikoya KA, Senbanjo IO, Njokanma OF. Parental reporting of suspected adverse drug reactions in children in Lagos, Nigeria. Arch Dis Child 2009;94:469–73.
Houghton J, Woods F, Davis S, Coulson R, Routledge PA. Community pharmacist reporting of suspected ADRs: (2) attitudes of community pharmacists and general practitioners in Wales. Pharm J 1999 Jan;263(7071):788-91.
Palaian S, Alshakka M, Izham M. Developing a consumer reporting program in Malaysia: a novel initiative to improve pharmacovigilance. Pharm World Sci 2010;32:2-6.
Herxheimer A, Crombag MR, Alves TL. Direct Patient reporting of adverse drug reactions-a twelve country survey and literature review. Health Action International Europe 2010 Jan. Available from: URL:http://www.haiweb.org/14012010/14Jan2010 ReportDirectPatientReportingofADRsFINAL.pdf.
Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hermandez-Diaz S, Lasheras B.Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf 2007;30 (11):1073-82.
Cordina M, Safta V, Ciobanu A, Sautenkova N. An assessment of community pharmacists’ attitudes towards professional practice in the Republic of Moldova. Pharmacy Practice 2008 Jan-Mar;6(1):1-8.
Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ. Influence of Pharmacists’ attitudes on adverse drug reaction reporting a case-control study in Portugal. Drug Saf 2006;29(4):331-40.
Mann RD. Prescription event monitoring - recent progress and future horizons. Br J Clin Pharmacol 1998;46:195-201.
Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998;45:496-500.
van Grootheest AC, Olsson S, Couper M, de Jong-van den Berg LTW. Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiology and Drug Saf 2004 Jul;13(7):457-64.
Hawksworth GM, Corlett AJ, Wright DJ, Chrystyn H. Clinical pharmacy interventions by community pharmacists during the dispensing process. Br J Clin Pharmacol 1999;47:695-700.
Nathan A, Goodyer L, Lovejoy A, Rashid A. ‘Brown bag’ medication reviews as a means of optimizing patients’ use of medication and of identifying potential clinical problems. Fam Pract 1999;16(3):278-82.
Toklu HZ, Uysal MK. The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul. Pharm World Sci 2008;30:556-62.
Ajuoga E, Sansgiry SS, Ngo C, Yeh RF. Use/misuse of over-the-counter medications and associated adverse drug events among HIV-infected patients. Res Social Adm Pharm 2008 Sep;4(3):292-301.
Cuzzolin L, Benoni G. Safety on non-prescription medincines: knowledge and attitudes of Italian pharmacy customers. Pharm World Sci 2010;32:97-102.
Olsson S. Pharmacovigilance training with focus on India. Indian J Pharmacol 2008 Feb;40(1):28-30.
Udupa N. Community pharmacy-current scenario and future prospects. Available from: URL:http://www.acpi.in/CPE Mangalore 2009/Current Scenario and Future Prospectus.pdf.
Elkalmi RM, Hassali MA, Ibrahim MIM, Shafie AA. Community pharmacists’involvement in the pharmacovigilance program in Malaysia. J Pharm Pract Res 2014;40(3):245-6.
Jha N, Bajracharya O, Namgyal T. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley. KUMJ 2007;5(20):504-10.
Pouyanne P, Haramburu F, Imbs JL, Bégaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000 Apr;320:1036.
Rao PGM, Archana B, Jose J. Implementation and results of an adverse drug reaction reporting programme at an Indian teaching hospital. Indian J Pharmacol 2006;38(4):2934.
Sharma H, Aqil M, Imam F, Alam MS, Kapur P, Pillai KK. A pharmacovigilance study in the department of medicine of a university teaching hospital. Pharmacy Practice 2007;5(1):46-9.
Palain S, Izham M, Mishra P. Monitoring adverse drug reactions using the community pharmacists: a preliminary study from Nepal. Drug Saf 2008;31(10):885-960.
Gandhi KT, Puopolo AL, Brennan TA.Drug complications in outpatients. J Gen Intern Med 2000; 15:149–54.
Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol 2007;65(2):210-16.
Martys CR. Adverse reactions to drugs in general practice. BMJ 1979;2:1194-97.
Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289(9):1107-16.
Naldi L et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999;48:839-846.
DOI: https://doi.org/10.37591/rrjopc.v8i2.1082
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Research & Reviews A Journal of Pharmacognosy